JAK-inhibition in Recurrent Classical Hodgkin Lymphoma
NCT02164500
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
12
Enrollment
OTHER
Sponsor class
Conditions
Recurrent Classical Hodgkin Lymphoma
Interventions
DRUG:
Ruxolitinib
Sponsor
University of Cologne